Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

Groundbreaking research unveils potential link between cytomegalovirus and Alzheimer's disease, offering new hope for ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state ... like when determining treatment eligibility. Placental growth factor, a blood ...